Deterioration of hematologic parameters in lymphoma patients is often attributed to disease progression, comorbidities, or treatment effects. Second primary malignancies occur at increased frequency in CLL and must also be considered.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044368 | PMC |
http://dx.doi.org/10.1002/ccr3.2656 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!